Please login to the form below

Not currently logged in
Email:
Password:

Tivicay

This page shows the latest Tivicay news and features for those working in and with pharma, biotech and healthcare.

GSK considers more divestments to help R&D push

GSK considers more divestments to help R&D push

HIV sales through the ViiV Healthcare joint venture showed signs of weakness, as Tivicay (dolutegravir) continued to decline in the face of strong competition from Gilead Sciences, particularly its fast-growing

Latest news

  • ViiV bags EU okay for new two-drug HIV therapy ViiV bags EU okay for new two-drug HIV therapy

    Dovato – a fixed-dose combination of ViiV’s blockbuster integrase inhibitor Tivicay (dolutegravir) and the nucleoside reverse transcriptase inhibitor lamivudine – is integral to the company’s attempt to muscle out

  • Shingrix lifts GSK in Q1, but two more vaccines are culled Shingrix lifts GSK in Q1, but two more vaccines are culled

    The bulk of GSK’s HIV sales come from its dolutegravir-based combination products Tivicay and Triumeq, but greater competition in the market from arch-rival Gilead Sciences with new products ... That was particularly apparent for three-drug combo

  • Dovato approval key for Glaxo in HIV treatment Dovato approval key for Glaxo in HIV treatment

    If the cost of prescribing Tivicay (dolutegravir) plus generic lamivudine is substantially lower than the cost of Dovato, it’s possible clinicians and payers could consider this approach.”.

  • Gilead awaits CEO and readouts to revive fortunes Gilead awaits CEO and readouts to revive fortunes

    It earned $551m in the fourth quarter and picked up both treatment-naïve patients and those switching from other drugs, including GSK’s rival drug Tivicay and its own established product

  • GSK’s says depot HIV injection works over three years GSK’s says depot HIV injection works over three years

    Earlier this year,   GSK won approval for oral two-drug regimen Juluca – based on integrase inhibitor Tivicay (dolutegravir) and rilpivirine – that aims to provide effective control of HIV with a single

More from news
Approximately 8 fully matching, plus 34 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Developing your patient-centric strategy

    The 2013 PatientView survey likely scored ViiV well on the product front too, as 2013 saw the company’s HIV therapy Tivicay (dolutegravir) approved in the US and recommended for European

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics